Penumbra
PEN · NYSE · Healthcare
$319.44
+$0.67 (+0.21%) today
Market Cap
$12.58B
24h Volume
$131.2M
P/E Ratio
78.7
52w High
$359.40
52w Low
$225.54
Est. AI Revenue
20%
7-Day Sparkline (Static)
Company facts
Performance
About Penumbra
Penumbra is a medical device company focused on removing blood clots. Its thrombectomy systems treat stroke and other clot conditions, and it earns revenue from hospitals buying devices and the consumables used in each procedure.
AI and robotics are its forward edge. Lightning AI Aspiration adjusts clot removal in real time, AI Stroke Imaging helps identify candidates for intervention, Intelligent Thrombectomy guides procedures, and the REAL Robotics AI program points toward robot-assisted neurovascular care.
Founded in 2004 and headquartered in Alameda, California, Penumbra trades on the NYSE and employs about 4,700 people under CEO Adam Elsesser.
Penumbra in the AI buildout
Penumbra sits in the AI Healthcare and Robotics & Automation layers, applying AI at the point of care rather than supplying the buildout. Its algorithms tune clot aspiration and read stroke imaging, and its robotics program extends that into procedure assistance. Revenue depends on procedure volumes and device adoption in hospitals, so AI and robotics support the products instead of driving the thesis. Supercycle scores its AI exposure at 12 out of 100.
PEN is tracked in AI Healthcare and Robotics & Automation, rated Peripheral on the AI Exposure leaderboard.
By the numbers
52-week range
PEN trades at $319.44, 70% of the way up its 52-week range of $225.54 to $359.40.
Market cap
Market capitalization is $12.58B, with an AI Exposure Score of 12 out of 100.
Valuation vs peers
Its P/E ratio of 78.7 is above the AI Healthcare category median of 29.6.
Next earnings
Penumbra is next expected to report earnings on November 4, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does Penumbra do?
Penumbra makes medical devices for removing blood clots, focused on stroke and neurovascular care. Hospitals buy its thrombectomy systems and per-procedure consumables, which is where the company earns its revenue.
How is Penumbra exposed to AI?
Modestly. AI appears in its imaging analysis, its Lightning aspiration technology, and an emerging robotics program, but revenue depends on procedure volumes and device adoption. Supercycle rates its AI Exposure Score at 12 out of 100.
What are Penumbra's main AI products?
Lightning AI Aspiration for real-time clot removal control, AI Stroke Imaging for identifying intervention candidates, Intelligent Thrombectomy for procedure guidance, and the REAL Robotics AI program for robot-assisted care.
Is PEN a pure play AI stock?
No. Penumbra is a medical device company where AI and robotics are supporting features in its clot removal systems. Its AI Exposure Score of 12 out of 100 reflects that peripheral position.
Where is Penumbra based and who leads it?
Penumbra is headquartered in Alameda, California, and led by CEO Adam Elsesser. Founded in 2004, the company employs about 4,700 people and its shares trade on the NYSE.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.